School of Pharmacy
Although statins and other pharmacological approaches have improved the management of lipid abnormalities, there exists a need for newer treatment modalities especially for the management of hypertriglyceridemia. Lipoprotein lipase (LPL), by promoting hydrolytic cleavage of the triglyceride core of lipoproteins, is a crucial node in the management of plasma lipid levels. Although LPL expression and activity modulation is observed as a pleiotropic action of some the commonly used lipid lowering drugs, the deliberate development of drugs targeting LPL has not occurred yet. In this review, we present the biology of LPL, highlight the LPL modulation property of currently used drugs and review the novel emerging approaches to target LPL.
Digital Commons Citation
Geldenhuys, Werner J.; Lin, Li; Darvesh, Altaf S.; and Sadana, Prabodh, "Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases" (2017). Clinical and Translational Science Institute. 583.
Geldenhuys WJ, Lin L, Darvesh AS, Sadana P. Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases. Drug Discovery Today. 2017;22(2):352-365. doi:10.1016/j.drudis.2016.10.007